Launch of FTMS Instruments Marks Varian’s Slow and Steady Entry Into Proteomics Space | GenomeWeb
As part of the company’s gradual entry into the proteomics space from the applied markets, Varian has refreshed its portfolio of Fourier transform mass spectrometers, replacing instruments it inherited as part of an acquisition made a year ago.
 
The company is also considering acquisitions and internal development efforts to fill a product gap between its low- and high-end mass specs.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.